New drug combination brings 1-2 punch against acute leukemia

Researchers at The University of Texas M. D. Anderson Cancer Center have discovered a drug combination that kills leukemia cells by shutting down their energy source and hastening cell starvation.

In a preclinical study, Lauren Akers, D.O., postdoctoral fellow from the Children's Cancer Hospital at M. D. Anderson, found that combining a novel glycolysis inhibitor, 3-BrOP, with mTOR inhibitor, rapamycin, induced more than 90 percent cell death in human tissue cultures of acute lymphocytic leukemia. She presented her study at the American Society of Pediatric Hematology/Oncology annual conference on May 16.

"We already knew that 3-BrOP was effective in preclinical research of glioblastoma, colon cancer and lymphoma, and most recently acute leukemias" says Akers, lead investigator on the study. "We also knew that mTOR inhibitors intensify cellular starvation. This study showed that the two together have a more powerful impact on treating acute lymphocytic leukemia, which is the most common childhood cancer."

Glycolysis is a process that turns glucose into energy for cells. Unlike healthy cells that get their energy for growth from both glycolysis and respiration, cancer cells are highly dependent on glycolysis. Using the M. D. Anderson-developed drug, 3-BrOP, researchers inhibited glycolysis, thus starving the leukemia cells from their energy source while leaving healthy cells free to get their energy from respiration.

Rapamycin is an mTOR inhibitor that keeps cancer cells from coping with stress, thus resulting in cell death. When researchers on the study combined the two drugs, they discovered a synergistic effect.

"We found that a lower dosage of 3-BrOP with rapamycin created the same results of more than 90 percent tumor cell death," says Akers. "Theoretically, we believe that patients will better tolerate the therapy by lowering the dosage of 3-BrOP and combining it with rapamycin."

Other researchers on the study include senior investigator Patrick Zweidler-McKay, M.D., Ph.D., Anna Franklin, M.D. and Wendy Fang, M.D., all from the Children's Cancer Hospital at M. D. Anderson. Peng Huang, M.D., Ph.D., from the Department of Molecular Pathology at M. D. Anderson was also an investigator and was responsible for the development of 3-BrOP.

The team of researchers plans to conduct additional mouse studies, which could lead to a Phase I clinical trial some time in the future.

Source: University of Texas M. D. Anderson Cancer Center

Related stories:

Landmark discovery of 'engine' that drives cell movement
This research by Thomas Leung, Ph.D., and his team in the GSK-IMCB Group at the Institute of Molecular and Cell Biology (IMCB), under Singapore's Agency for Science, Technology and Research, is fundamental to the understanding of how assembles its internal machinery required for cell movement.
Brazilian acai berry antioxidants absorbed by human body
A Brazilian palm berry, popular health food though little research has been done on it, now may have its purported benefits better understood. In the first research involving people, the acai (ah-sigh-EE) berry has proven its ability to be absorbed in the human body when consumed both as juice and pulp. That finding, by a team of Texas AgriLife Research scientists, was published in a recent issue of the Journal of Agricultural and Food Chemistry.
Nanoscopic screening process to speed drug discovery
Researchers at Wake Forest University are using nanotechnology to search for new cancer-fighting drugs through a process that could be up to 10,000 times faster than current methods.
Scientists identify a molecule that coordinates the movement of cells
Even cells commute. To get from their birthplace to their work site, they sequentially attach to and detach from an elaborate track of exceptionally strong proteins known as the extracellular matrix. Now, in research to appear in the October 3 issue of Cell, scientists at the Howard Hughes Medical Institute and Rockefeller University show that a molecule, called ACF7, helps regulate and power this movement from the inside - findings that could have implications for understanding how cancer cells metastasize.
Philips develops ultrasound-activated microbubbles for localized delivery of cancer drugs
(PhysOrg.com) -- Philips is developing an ultrasound-based drug delivery technology that is designed to increase the effectiveness and reduce the side effects of chemotherapy treatment for certain types of cancer.
Existing anti-obesity drugs may be effective against flu, hepatitis and HIV
Viruses dramatically increase cellular metabolism, and existing anti-obesity drugs may represent a new way to block these metabolic changes and inhibit viral infection, according to a study published today in the journal Nature Biotechnology.
New technology paves the way for the future of identifying proteins inside cells
A new technology which enables scientists to identify proteins by making a map of the energy flow inside the protein is revealed today in Proceedings of the National Academy of Sciences (PNAS) journal.
Golden Nanorods for Medical Applications
(PhysOrg.com) -- Gold nanoparticles are under consideration for a number of biomedical applications, such as tumor treatment. A German-American research team at Carnegie Mellon University in Pittsburgh, Hunter College in New York, and the RWTH Aachen has now developed a new method for the production of nanoscopic gold rods. In contrast to previous methods, they have achieved this without the use of cytotoxic additives. As they report in the journal Angewandte Chemie, the synthesis is not carried out in water, but in an ionic liquid, a “liquid salt”.

News discussion:

Medicine & Health news